Table 5 Completed and ongoing clinical trials targeting galectins in oncology
From: Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy
NCT Number | Intervention | Target | Condition | Phase | Status |
|---|---|---|---|---|---|
NCT05240131 | GB1211 combined with Atezolizumab | Gal-3 | Non-small cell lung cancer | I/II | Recruiting |
NCT01724320 | OTX008 | Gal-1 | Solid tumors | I | Unknown |
NCT02575404 | GR-MD-02 combined with Pembrolizumab (anti-PD-L1) | Gal-3 | Melanoma, non-small cell lung cancer, and squamous cell head and neck cancers | I | Active, not recruiting |
NCT00388700 | GM-CT-01 combined with 5-FU, Avastin and Leucovorin | Gal-1&3 | Colorectal cancer | II | Withdrawn |
NCT00110721 | GM-CT-01 plus 5-FU | Gal-1&3 | Colorectal cancer | II | Terminated |
NCT00386516 | GM-CT-01 combined with 5-FU | Gal-1&3 | Bile duct cancer Gallbladder cancer | II | Withdrawn |
NCT00054977 | GM-CT-01 with and without 5-FU | Gal-1&3 | Colorectal, lung, breast, head and neck, and prostate cancers | I | Completed |
NCT04666688 | LYT-200 alone or combined with Gemcitabine/nab-paclitaxel or Anti-PD-1 | Gal-9 | Metastatic cancer, solid tumor, cholangiocarcinoma | I/II | Recruiting |
NCT04987996 | GR-MD-02 plus Pembrolizumab or Pembrolizumab | Gal-3 | Melanoma, head and neck squamous cell carcinoma | II | Suspended |
NCT01681823 | Dietary Supplement: PectaSol-C Modified Citrus Pectin (MCP) | Gal-3 | Prostatic neoplasms | II | Completed |
NCT01723813 | Peptide vaccinations plus GM-CT-01 | Gal-3 | Metastatic melanoma | I/II | Terminated |
NCT02117362 | GR-MD-02 and Ipilimumab | Gal-3 | Metastatic melanoma | I | Completed |
NCT00776802 | GCS-100 combined with Etoposide and Dexamethasone | Gal-3 | Diffuse large B-cell lymphoma | I/II | Withdrawn |